Back to Search
Start Over
The effect of ellagic acid on sex hormones and miRNA-21 expression in rats with polycystic ovary syndrome.
- Source :
-
Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2024 Jun; Vol. 397 (6), pp. 4263-4273. Date of Electronic Publication: 2023 Dec 11. - Publication Year :
- 2024
-
Abstract
- Purpose: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects women of reproductive age. It is characterized by irregular menstrual cycles, hyperandrogenism, and polycystic ovaries. The syndrome's etiology is multifactorial, involving genetic, hormonal, metabolic, and environmental factors. Given its diverse effects, managing PCOS requires a comprehensive approach.<br />Methods: This study employed a Sprague-Dawley rat model to investigate the effects of ellagic acid on polycystic ovary syndrome (PCOS). Forty adult female rats were randomly divided into four groups: a control group, a healthy group receiving ellagic acid (200 mg/kg), a PCOS group, and an ellagic acid + PCOS group. PCOS was induced in the relevant groups through subcutaneous injection of estradiol valerate (2 mg/kg), and ellagic acid was administered via subcutaneous injections for 14 days. Blood samples were collected for hormone analysis using the ELISA method, and ovarian tissues were processed for histological examination.<br />Result: Ellagic acid treatment showed reduced LH levels and restoration of follicular development, particularly primordial and graafian follicles, along with modulation of miRNA-21 expression. Moreover, ellagic acid exhibited positive effects on ovarian morphology, including decreased theca layer thickness, increased oocyte diameter, and improvements in antral and preovulatory follicles. This suggests ellagic acid's potential in addressing follicular development and oocyte quality in PCOS.<br />Conclusions: These findings suggest ellagic acid as a potential complementary approach in PCOS management. While the study is promising, further research, including clinical trials, is required to elucidate ellagic acid's mechanisms and clinical efficacy in human PCOS subjects.<br /> (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Subjects :
- Animals
Female
Ovary drug effects
Ovary metabolism
Ovary pathology
Rats
Luteinizing Hormone blood
Gonadal Steroid Hormones blood
Disease Models, Animal
Estradiol pharmacology
Estradiol blood
Polycystic Ovary Syndrome drug therapy
Polycystic Ovary Syndrome chemically induced
Polycystic Ovary Syndrome metabolism
Polycystic Ovary Syndrome pathology
Ellagic Acid pharmacology
Rats, Sprague-Dawley
MicroRNAs genetics
MicroRNAs metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1432-1912
- Volume :
- 397
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Naunyn-Schmiedeberg's archives of pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 38078918
- Full Text :
- https://doi.org/10.1007/s00210-023-02895-7